Saltar al contenido
Merck

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.

Haematologica (2019-05-11)
Salih Demir, Elena Boldrin, Qian Sun, Stephanie Hampp, Eugen Tausch, Cornelia Eckert, Martin Ebinger, Rupert Handgretinger, Geertruy Te Kronnie, Lisa Wiesmüller, Stephan Stilgenbauer, Galina Selivanova, Klaus-Michael Debatin, Lüder Hinrich Meyer
RESUMEN

Alterations of the tumor suppressor gene TP53 are found in different cancers, in particular in carcinomas of adults. In pediatric acute lymphoblastic leukemia (ALL), TP53 mutations are infrequent but enriched at relapse. As in most cancers, mainly DNA-binding domain missense mutations are found, resulting in accumulation of mutant p53, poor therapy response, and inferior outcome. Different strategies to target mutant p53 have been developed including reactivation of p53's wildtype function by the small molecule APR-246. We investigated TP53 mutations in cell lines and 62 B-cell precursor ALL samples and evaluated the activity of APR-246 in TP53-mutated or wildtype ALL. We identified cases with TP53 missense mutations, high (mutant) p53 expression and insensitivity to the DNA-damaging agent doxorubicin. In TP53-mutated ALL, APR-246 induced apoptosis showing strong anti-leukemia activity. APR-246 restored mutant p53 to its wildtype conformation, leading to pathway activation with induction of transcriptional targets and re-sensitization to genotoxic therapy in vitro and in vivo In addition, induction of oxidative stress contributed to APR-246-mediated cell death. In a preclinical model of patient-derived TP53-mutant ALL, APR-246 reduced leukemia burden and synergized strongly with the genotoxic agent doxorubicin, leading to superior leukemia-free survival in vivo Thus, targeting mutant p53 by APR-246, restoring its tumor suppressive function, seems to be an effective therapeutic strategy for this high-risk group of TP53-mutant ALL.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-p53 (wild type) Antibody, clone PAb1620, clone Pab1620, from mouse
Sigma-Aldrich
Anti-PUMA/bbc3, N-Terminal antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution